| Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase III CAIRO4 study conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer Group.Ann Oncol | PMID 38852675无 PMCID | 2024-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and safety of ongericimab given by prefilled syringe or autoinjector in primary hypercholesterolemia and mixed hyperlipidemia.Nutr Metab Cardiovasc Dis | PMID 38866609无 PMCID | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| First-line bevacizumab plus chemotherapy in Chinese patients with stage III/IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer: a phase III randomized controlled trial.J Gynecol Oncol | PMID 38872480PMC11390243 | 2024-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26 Weeks Treatment.Endocr Pract | PMID 38876181无 PMCID | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Low-dose ondansetron: A candidate prospective precision medicine to treat alcohol use disorder endophenotypes.Eur J Intern Med | PMID 38876929无 PMCID | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Roxadustat versus placebo for patients with lower-risk myelodysplastic syndrome: MATTERHORN phase 3, double-blind, randomized controlled trial.Am J Hematol | PMID 38884137无 PMCID | 2024-Sep | 0.85 | The study is a Phase III randomized, double-blind, drug-intervention trial with original final results for an oncology (myelodysplastic syndrome) indication. However, the primary efficacy endpoint is transfusion independence (TI), a binary response endpoint, not a time-to-event endpoint such as OS, PFS, DFS, EFS, RFS, or TTP. No Kaplan-Meier curves or hazard ratios for time-to-event outcomes are reported in the abstract. Therefore, it does not meet the requirement for a primary/key secondary time-to-event efficacy endpoint. | 待处理 |
| Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition.Am J Hematol | PMID 38884175无 PMCID | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study.Breast Cancer | PMID 38884900PMC11341650 | 2024-Sep | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study.Int J Hematol | PMID 38888812PMC11362427 | 2024-Sep | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial.Br J Cancer | PMID 38906970PMC11333611 | 2024-Sep | 0.95 | The study is a Phase III randomized trial with a drug-containing intervention in oncology, but the primary efficacy endpoint is total pathologic complete response (tpCR), which is not a time-to-event endpoint. No time-to-event endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP), Kaplan-Meier analysis, or hazard ratio is reported. Therefore, it does not meet the inclusion criterion for a primary/key secondary time-to-event efficacy endpoint. | 待处理 |
| Efficacy and Safety of Ganyushu Granule in Treatment of Premenstrual Syndrome with Gan (Liver) Depression and Qi Stagnation Syndrome: A Randomized, Double-Blind, Multicenter, Phase-II Clinical Trial.Chin J Integr Med | PMID 38907069无 PMCID | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Collateral-based selection for endovascular treatment of acute ischaemic stroke in the late window (MR CLEAN-LATE): 2-year follow-up of a phase 3, multicentre, open-label, randomised controlled trial in the Netherlands.Lancet Neurol | PMID 38909624无 PMCID | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria.Am J Hematol | PMID 38924124无 PMCID | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term tafamidis efficacy in patients with transthyretin amyloid cardiomyopathy by baseline left ventricular ejection fraction.Eur J Heart Fail | PMID 38932583无 PMCID | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Informing the Recommended Phase III Dose of Alnuctamab, a CD3 × BCMA T-Cell Engager, Using Population Pharmacokinetics and Exposure-Response Analysis.Clin Pharmacol Ther | PMID 38938115无 PMCID | 2024-Sep | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 待处理 |
| Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA.Ann Oncol | PMID 38942080无 PMCID | 2024-Sep | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trial.Nat Med | PMID 38942993无 PMCID | 2024-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| SERENE ER Analysis Part 1-SERENE CD: Exposure-Response Analysis of Higher Versus Standard Adalimumab Dosing Regimens for Patients With Moderately to Severely Active Crohn Disease.Clin Pharmacol Drug Dev | PMID 38953542无 PMCID | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| SERENE ER Analysis Part 2 SERENE-UC: Exposure-response Analysis of Higher Versus Standard Adalimumab Dosing Regimens for Patients with Moderately to Severely Active Ulcerative Colitis.Clin Pharmacol Drug Dev | PMID 38953600无 PMCID | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Brodalumab, an Anti-interleukin-17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16-Week Results of a Randomized Clinical Trial.Am J Clin Dermatol | PMID 38954226PMC11358179 | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.Nat Med | PMID 38956195PMC11405280 | 2024-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105).Breast Cancer Res Treat | PMID 38967884PMC11297090 | 2024-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Prevention of post COVID-19 condition by early treatment with ensitrelvir in the phase 3 SCORPIO-SR trial.Antiviral Res | PMID 38972603无 PMCID | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Dual add-on therapy of gemigliptin and dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone: The SOLUTION 2 study.Diabetes Obes Metab | PMID 38978173无 PMCID | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer.Cancer Sci | PMID 38979893PMC11462951 | 2024-Sep | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial.Diabetologia | PMID 38985161PMC11410852 | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial.Diabetologia | PMID 38985162PMC11410837 | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of eculizumab in Guillain-Barré syndrome: A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial.J Peripher Nerv Syst | PMID 38987228无 PMCID | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2.Adv Ther | PMID 38990433PMC11349857 | 2024-Sep | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy.Eur J Cancer | PMID 39013265无 PMCID | 2024-Sep | 0.85 | The record describes a safety/tolerability analysis from a Phase III trial, not an efficacy analysis with a time-to-event endpoint. | 待处理 |
| Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS).Cancer Commun (Lond) | PMID 39016053PMC11492357 | 2024-Sep | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Effect of a comprehensive lifestyle intervention program on body weight and health behavior in women with breast cancer: Results from a randomized controlled trial.Clin Nutr | PMID 39024773无 PMCID | 2024-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial.Lancet Haematol | PMID 39033767无 PMCID | 2024-Sep | 0.95 | The record meets all eligibility criteria: a randomized, double-blind, Phase 3 trial in human oncology (low-risk del(5q) myelodysplastic syndromes) with a drug-containing intervention (lenalidomide) and a primary time-to-event efficacy endpoint (time to transfusion dependency) reported with hazard ratio and p-value. It is an original primary result report. | 待处理 |
| Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial.Lancet Haematol | PMID 39038479无 PMCID | 2024-Sep | 0.90 | The study is an eligible oncology Phase III randomized trial with a drug intervention and original results, but the primary endpoint is a categorical response rate (transfusion independence), not a time-to-event endpoint like OS or PFS, and no Kaplan-Meier or HR for such an endpoint is reported. | 待处理 |
| Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in diabetic macular edema: 2-year results from the Japan subgroup of the phase 3 YOSEMITE trial.Jpn J Ophthalmol | PMID 39083147PMC11420323 | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow-up in the SELECTION open-label long-term extension study.Aliment Pharmacol Ther | PMID 39086130无 PMCID | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial.Lancet Diabetes Endocrinol | PMID 39089293无 PMCID | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol | PMID 39102832无 PMCID | 2024-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A randomized, double-blind, placebo-controlled trial to evaluate the effect of nabiximols oromucosal spray on clinical measures of spasticity in patients with multiple sclerosis.Mult Scler Relat Disord | PMID 39106541无 PMCID | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Momelotinib versus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: an efficacy/safety analysis in the Japanese subgroup of the phase 3 randomized SIMPLIFY-1 trial.Int J Hematol | PMID 39110143PMC11362197 | 2024-Sep | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 待处理 |
| Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer.Eur J Cancer | PMID 39111209无 PMCID | 2024-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimab.Pharmacol Res | PMID 39111557无 PMCID | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| HARMONIZE Asia: A Phase III Randomized Study to Investigate the Efficacy and Safety of Sodium Zirconium Cyclosilicate in Patients with Hyperkalemia in China.Clin Ther | PMID 39112102无 PMCID | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of insomnia treatment with lemborexant in older adults: analyses from three clinical trials.Drugs Aging | PMID 39120786PMC11408585 | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial.Lancet Oncol | PMID 39121881无 PMCID | 2024-Sep | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Postoperative radiotherapy in women with early operable breast cancer (Scottish Breast Conservation Trial): 30-year update of a randomised, controlled, phase 3 trial.Lancet Oncol | PMID 39127062无 PMCID | 2024-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial.Lancet Oncol | PMID 39127063无 PMCID | 2024-Sep | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.Lancet Oncol | PMID 39146951无 PMCID | 2024-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Safety and efficacy of intra-erythrocyte dexamethasone sodium phosphate in children with ataxia telangiectasia (ATTeST): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.Lancet Neurol | PMID 39152028无 PMCID | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting.J Comp Eff Res | PMID 39162049PMC11363176 | 2024-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |